Neoadjuvant Radiotherapy with Camrelizumab as a Chemotherapy-Sparing Strategy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase II Trial (ESOCORT-NIRT) - Top-Institutions - MDSpire

Neoadjuvant Radiotherapy with Camrelizumab as a Chemotherapy-Sparing Strategy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase II Trial (ESOCORT-NIRT)

  • By

  • Maohui Chen

  • Yizhou Huang

  • Shuliang Zhang

  • Cheng Chen

  • Taidui Zeng

  • Hongmu Li

  • Zhenyuan Yang

  • Chuanquan Lin

  • Wei Li

  • Benhua Xu

  • Chun Chen

  • Bin Zheng

  • March 9, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Chinese Academy of Medical Sciences Cancer Hospital (National Cancer Center, China)
    Chinese Academy of Medical Sciences Cancer Hospital (National Cancer Center, China)

    Beijing, Beijing

    Key Differentiators

    • Medical Oncology
    • Radiation Oncology
    • Surgical Oncology
    • Immunotherapy

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Medical Oncology
    • Radiation Oncology
    • Surgical Oncology
    • Immunotherapy

  • #3

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Medical Oncology
    • Radiation Oncology
    • Surgical Oncology
    • Immunotherapy

  • #4

    National Cancer Center Hospital East
    National Cancer Center Hospital East

    Kashiwa, Chiba

    Key Differentiators

    • Medical Oncology
    • Radiation Oncology
    • Surgical Oncology

  • #5

    Fudan University Shanghai Cancer Center
    Fudan University Shanghai Cancer Center

    Shanghai, Shanghai

    Key Differentiators

    • Medical Oncology
    • Radiation Oncology
    • Surgical Oncology
    • Immunotherapy

Original Source(s)

Neoadjuvant Radiotherapy with Camrelizumab as a Chemotherapy-Sparing Strategy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase II Trial (ESOCORT-NIRT)

  • by Maohui Chen, Yizhou Huang, Shuliang Zhang, Cheng Chen, Taidui Zeng, Hongmu Li, Zhenyuan Yang, Chuanquan Lin, Wei Li, Benhua Xu, Chun Chen, Bin Zheng

  • March 9, 2026

Related Content

Differentiation of hepatocellular carcinoma from hepatic hemangioma using diffusion-derived vessel density map-based radiomics features

Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study

Emerging applications of artificial intelligence for risk stratification in head and neck cancer: a scoping review